The affected product (batch number 2310083) was manufactured by CoreRx in Clearwater, Fla., and distributed nationwide between December 2023 and 2024, according to a Sept. 17 FDA news release.
The release warned microbial contamination poses a serious risk, especially for immunocompromised individuals, as it can lead to life-threatening infections, including inflammation of the heart and permanent soft tissue damage.
Consumers are advised to stop using the affected batch and return it to the place of purchase, the release said.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
